Need more? Try out  Advanced Search (20+ criteria)»

logo

Last Update

This profile was last updated on 5/4/2017 and contains contributions from the  Zoominfo Community.

is this you? Claim your profile.

Wrong Joseph O'Neill?

Joseph F. O'Neill

Deputy Coordinator and Chief Medical Officer, Office of the Global AIDS Coordinator

U.S. Department of State

HQ Phone:  (202) 647-4000

GET ZOOMINFO GROW

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions.

I agree to the  Terms of Service and  Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

THANK YOU FOR DOWNLOADING!

computers
  • 1.Download
    ZoomInfo Grow
    v sign
  • 2.Run Installation
    Wizard
  • 3.Check your inbox to
    Sign in to ZoomInfo Grow

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

U.S. Department of State

2201 C St., NW

Washington, D.C., District of Columbia,20520

United States

Company Description

Founded in 1986, the U.S. Department of State's au pair program allows 18 to 26-year-old international visitors who travel to the U.S. on a J-1 Visitor Exchange Visa to acquire a better understanding and appreciation of American life while living with an Ameri... more

Find other employees at this company (10,204)

Background Information

Employment History

Director - Information Technology Data Management and Records

University of Illinois System


Chief Executive Officer

APCA


Member, Health Resources and Services Administration

HIV Testing


Head of HIV and AIDS Programs

HHS


Head of the Office of AIDS

Department of Health and Human Services


President and Chief Executive Officer

The Immune Response Corporation


President and Chief Executive Officer

Orchestra Therapeutics, Inc.


Named Deputy Coordinator, Chief Medical Officer

the State Department


Head of HHS' Office

AIDS Survival Project Inc


Chief Executive Officer and President

The Immune Response Corporation


Consultant To the Vice President for Economic Development

University of Illinois


Chief Resident for the Department of Medicine

University of Washington


Affiliations

Promoting Excellence

Advisor


Fyodor Biotechnologies , Inc.

Board Member


Maryland Global Initiatives Corporation

Founding Member of the Board


Johns Hopkins University

Practicing HIV and AIDS Physician, A Volunteer Member of the Faculty


University of Maryland

Teacher


Jonas Salk Legacy Foundation

BOARD OF ADVISORS Member


Switchboard

Board Member


Social & Scientific Systems Inc

Strategic Advisory Board Member


The Robert Wood Johnson Foundation's Promoting Excellence in End-of-Life Care program and

Member, Advisory Boards


Spencer Trask Ventures Inc

Board Member


NATAP

Board Member


Academy for Educational Development

Board Member


White House

Director


Education

School of Medicine of the University of California at San Francisco


Bachelor's degree

business administration

University of California at Berkeley


M.D.


M.P.H.


Master's degrees

public health and medical sciences

University of California at Berkeley


advanced degrees

business administration , public health , health and medical sciences

University of California at Berkeley


degree

palliative medicine

University of Cape Town


degrees

Business Administration , Public Health , Health Sciences and Medicine

Universities of California at Berkeley and San Francisco


degrees

Business Administration , Public Health , and Health and Medical Sciences

UC Berkeley


Web References(111 Total References)


www.africanpalliativecare.org

Dr. Joseph F. O'Neill M.D. (International Advisor)
Dr. O'Neill has an extensive record of public service spanning multiple U.S. administrations. He served as Deputy U.S. Global AIDS Coordinator and Chief Medical Officer for the Office of the Global AIDS Coordinator at the U.S. Department of State. During his tenure, the Office of the U.S. Global AIDS Coordinator oversaw the disbursement of $2.4 billion to over 100 countries in the first year of operations. Prior to that position, Dr. O'Neill was the Director of the White House Office of National AIDS Policy where he spearheaded the development of PEPFAR, and coordinated the successful legislative strategy resulting in the passage by Congress of the U.S. Leadership against HIV/AIDS, Tuberculosis, and Malaria Act of 2003. Previously, Dr. O'Neill also served as the Acting Director of the Office of HIV/AIDS Policy in the Department of Health and Human Services, coordinating the Department's $30 billion HIV/AIDS program. He also served as Director of the HIV/AIDS Bureau of the Health Resources and Services Administration, responsible for management of the $1.9 billion Ryan White CARE program, the nation's largest healthcare program serving people living with AIDS. Dr. O'Neill is a practicing HIV/AIDS physician and a member of the faculties of the Johns Hopkins School of Medicine and the University of Maryland School of Medicine. He was also previously on the medical staff of the Chase Brexton Clinic, a community-based AIDS clinic in Baltimore. A graduate of the School of Medicine of the University of California at San Francisco, Dr. O'Neill also received Master's degrees in public health and medical sciences and a Bachelor's degree in business administration from the University of California at Berkeley.


www.promotingexcellence.org [cached]

Joseph F. O'Neill, M.D., M.P.H.
Deputy Coordinator and Chief Medical Officer Office of the Global AIDS Coordinator (S/GAC) U. S. Department of State


secure.spencertrask.com [cached]

Joseph F. O'Neill, M.D., Former Director of the Office of National AIDS Policy, Joins The Immune Response Corporation as CEOJoseph F. O'Neill, M.D., Former Director of the Office of National AIDS Policy, Joins The Immune Response Corporation as CEO - Tuesday, November 01, 2005CARLSBAD, Calif.--(BUSINESS WIRE)--Nov. 1, 2005--The Immune Response Corporation (Nasdaq Capital Market:IMNR) announced today the appointment of Joseph F. O'Neill, M.D., M.P.H. as its new Chief Executive Officer and President, succeeding John N. Bonfiglio, Ph.D.Dr. O'Neill comes to The Immune Response Corporation after a distinguished career leading federal AIDS policy at the White House, the Office of the U.S. Secretary of Health and Human Services, and the Office of the Global AIDS Coordinator at the U.S. Department of State.Dr. O'Neill was chief architect of the President's 2003 Emergency Plan for AIDS Relief, known as PEPFAR, a $15 billion U.S. Government-led global initiative to combat the HIV/AIDS epidemic.He will leverage his extensive experience and relationships in public health initiatives to lead the Company in the ongoing development of its products for HIV and multiple sclerosis (MS).Dr. O'Neill will also serve on the Company's Board of Directors. "I am thrilled to take on this challenge and dedicate my efforts to the development of Immune Response's products, which represent a powerful new therapeutic approach," said Dr. O'Neill.Dr. O'Neill has an extensive record of public service spanning multiple administrations.He served as Deputy U.S. Global AIDS Coordinator and Chief Medical Officer for the Office of the Global AIDS Coordinator at the U.S. Department of State.During his tenure, the Office of the U.S. Global AIDS Coordinator oversaw the disbursement of $2.4 billion to over 100 countries in the first year of operations.Prior to that position, Dr. O'Neill was the Director of the White House Office of National AIDS Policy where he spearheaded the development of PEPFAR, and coordinated the successful legislative strategy resulting in the passage by Congress of the U.S. Leadership against HIV/AIDS, Tuberculosis, and Malaria Act of 2003. Previously, Dr. O'Neill also served as the Acting Director of the Office of HIV/AIDS Policy in the Department of Health and Human Services, coordinating the Department's $30 billion HIV/AIDS program.He also served as Director of the HIV/AIDS Bureau of the Health Resources and Services Administration, responsible for management of the $1.9 billion Ryan White CARE program, the nation's largest healthcare program serving people living with AIDS. "I can't think of a more capable and accomplished person than Joe O'Neill to lead our Company into its next era," said Bob Knowling, Chairman of the Board of The Immune Response Corporation."Joe brings a unique perspective from his work on the front lines treating patients and his understanding of the plight of those suffering from this epidemic, combined with unparalleled experience implementing global health initiatives.We are honored that he will put that same passion, dedication and experience to work at the Immune Response Corporation." Dr. O'Neill is a practicing HIV/AIDS physician and a member of the faculties of the Johns Hopkins School of Medicine and the University of Maryland School of Medicine.He was also previously on the medical staff of the Chase Brexton Clinic, a community-based AIDS clinic in Baltimore.A graduate of the School of Medicine of the University of California at San Francisco, Dr. O'Neill also received Master's degrees in public health and medical sciences and a Bachelor's degree in business administration from the University of California at Berkeley. To further align Dr. O'Neill's interests with those of Immune Response stockholders, the Company's Board of Directors granted Dr. O'Neill an inducement stock option award.NASDAQ rules require disclosure of the terms of such awards.Dr. O'Neill received an option to buy 6,000,000 shares of Immune Response common stock at an exercise price of $0.32 per share.The option is subject to vesting requirements, as follows: 3,000,000 of the options shall vest quarterly over two years subject to Dr. O'Neill's continuation of service as CEO; and the remaining 3,000,000 options shall all vest in 2012, subject to Dr. O'Neill's continuation of service as CEO, unless they vest earlier based upon attainment of performance milestones which may be mutually agreed upon in the future by the Company and Dr. O'Neill. Forward-looking Statements This news release contains forward-looking statements.Forward-looking statements are often signaled by forms of words such as should, could, will, might, plan, projection, forecast, expect, guidance, potential and developing.Actual results could vary materially from those expected due to a variety of risk factors, including whether the Company will continue as a going concern and successfully raise proceeds from financing activities sufficient to fund operations and additional clinical trials of REMUNE®, NeuroVax(TM) or IR103, the uncertainty of successful completion of any such clinical trials, the fact that the Company has not succeeded in commercializing any drug, the risk that REMUNE®, NeuroVax(TM) or IR103 might not prove to be effective as either a therapeutic or preventive vaccine, whether future trials will be conducted and whether the results of such trials will coincide with the results of REMUNE®, NeuroVax(TM) or IR103 in preclinical trials and/or earlier clinical trials, and any transition issues related to the hiring of Dr. O'Neill.


www.imnr.com

Joseph F. O’Neill, M.D., Former Director of The Office of National AIDS Policy, Joins The Immune Response Corporation As CEO and PresidentThe Immune Response CorporationJoseph F. O'Neill, M.D., Former Director of The Office of National AIDS Policy, Joins The Immune Response Corporation As CEO and PresidentCARLSBAD, CA - November 1, 2005 - The Immune Response Corporation (Nasdaq Capital Market: IMNR) announced today the appointment of Joseph F. O'Neill, M.D., M.P.H. as its new Chief Executive Officer and President, succeeding John N. Bonfiglio, Ph.D.Dr. O'Neill comes to The Immune Response Corporation after a distinguished career leading federal AIDS policy at the White House, the Office of the U.S. Secretary of Health and Human Services, and the Office of the Global AIDS Coordinator at the U.S. Department of State.Dr. O'Neill was chief architect of the President's 2003 Emergency Plan for AIDS Relief, known as PEPFAR, a $15 billion U.S. Government led global initiative to combat the HIV/AIDS epidemic.He will leverage his extensive experience and relationships in public health initiatives to lead the Company in the ongoing development of its products for HIV and multiple sclerosis (MS).Dr. O'Neill will also serve on the Company's Board of Directors."I am thrilled to take on this challenge and dedicate my efforts to the development of Immune Response's products, which represent a powerful new therapeutic approach," said Dr. O'Neill.Dr. O'Neill has an extensive record of public service spanning multiple administrations.He served as Deputy U.S. Global AIDS Coordinator and Chief Medical Officer for the Office of the Global AIDS Coordinator at the U.S. Department of State.During his tenure, the Office of the U.S. Global AIDS Coordinator oversaw the disbursement of $2.4 billion to over 100 countries in the first year of operations.Prior to that position, Dr. O'Neill was the Director of the White House Office of National AIDS Policy where he spearheaded the development of PEPFAR, and coordinated the successful legislative strategy resulting in the passage by Congress of the U.S. Leadership against HIV/AIDS, Tuberculosis, and Malaria Act of 2003. Previously, Dr. O'Neill also served as the Acting Director of the Office of HIV/AIDS Policy in the Department of Health and Human Services, coordinating the Department's $30 billion HIV/AIDS program.He also served as Director of the HIV/AIDS Bureau of the Health Resources and Services Administration, responsible for management of the $1.9 billion Ryan White CARE program, the nation's largest health care program serving people living with AIDS."I can't think of a more capable and accomplished person than Joe O'Neill to lead our Company into its next era," said Bob Knowling, Chairman of the Board of The Immune Response Corporation."Joe brings a unique perspective from his work on the front lines treating patients and his understanding of the plight of those suffering from this epidemic, combined with unparalleled experience implementing global health initiatives.We are honored that he will put that same passion, dedication and experience to work at the Immune Response Corporation." Dr. O'Neill is a practicing HIV/AIDS physician and a member of the faculties of the Johns Hopkins School of Medicine and the University of Maryland School of Medicine.He was also previously on the medical staff of the Chase Brexton Clinic, a community-based AIDS clinic in Baltimore.A graduate of the School of Medicine of the University of California at San Francisco, Dr. O'Neill also received Master's degrees in public health and medical sciences and a Bachelor's degree in business administration from the University of California at Berkeley. To further align Dr. O'Neill's interests with those of Immune Response stockholders, the Company's Board of Directors granted Dr. O'Neill an inducement stock option award.Nasdaq rules require disclosure of the terms of such awards.Dr. O'Neill received an option to buy 6,000,000 shares of Immune Response common stock at an exercise price of $0.32 per share.The option is subject to vesting requirements, as follows: 3,000,000 of the options shall vest quarterly over two years subject to Dr. O'Neill's continuation of service as CEO; and the remaining 3,000,000 options shall all vest in 2012, subject to Dr. O'Neill's continuation of service as CEO, unless they vest earlier based upon attainment of performance milestones which may be mutually agreed upon in the future by the Company and Dr. O'Neill.Forward-looking StatementsThis news release contains forward-looking statements.Forward-looking statements are often signaled by forms of words such as should, could, will, might, plan, projection, forecast, expect, guidance, potential and developing.Actual results could vary materially from those expected due to a variety of risk factors, including whether the Company will continue as a going concern and successfully raise proceeds from financing activities sufficient to fund operations and additional clinical trials of REMUNE®, NeuroVax or IR103, the uncertainty of successful completion of any such clinical trials, the fact that the Company has not succeeded in commercializing any drug, the risk that REMUNE®, NeuroVax or IR103 might not prove to be effective as either a therapeutic or preventive vaccine, whether future trials will be conducted and whether the results of such trials will coincide with the results of REMUNE®, NeuroVax or IR103 in preclinical trials and/or earlier clinical trials, and any transition issues related to the hiring of Dr. O'Neill.


www.spencertrask.com

Joseph F. O'Neill, M.D., Former Director of the Office of National AIDS Policy, Joins The Immune Response Corporation as CEOJoseph F. O'Neill, M.D., Former Director of the Office of National AIDS Policy, Joins The Immune Response Corporation as CEO CARLSBAD, Calif.--(BUSINESS WIRE)--Nov. 1, 2005--The Immune Response Corporation (Nasdaq Capital Market:IMNR) announced today the appointment of Joseph F. O'Neill, M.D., M.P.H. as its new Chief Executive Officer and President, succeeding John N. Bonfiglio, Ph.D.Dr. O'Neill comes to The Immune Response Corporation after a distinguished career leading federal AIDS policy at the White House, the Office of the U.S. Secretary of Health and Human Services, and the Office of the Global AIDS Coordinator at the U.S. Department of State.Dr. O'Neill was chief architect of the President's 2003 Emergency Plan for AIDS Relief, known as PEPFAR, a $15 billion U.S. Government-led global initiative to combat the HIV/AIDS epidemic.He will leverage his extensive experience and relationships in public health initiatives to lead the Company in the ongoing development of its products for HIV and multiple sclerosis (MS).Dr. O'Neill will also serve on the Company's Board of Directors. "I am thrilled to take on this challenge and dedicate my efforts to the development of Immune Response's products, which represent a powerful new therapeutic approach," said Dr. O'Neill.Dr. O'Neill has an extensive record of public service spanning multiple administrations.He served as Deputy U.S. Global AIDS Coordinator and Chief Medical Officer for the Office of the Global AIDS Coordinator at the U.S. Department of State.During his tenure, the Office of the U.S. Global AIDS Coordinator oversaw the disbursement of $2.4 billion to over 100 countries in the first year of operations.Prior to that position, Dr. O'Neill was the Director of the White House Office of National AIDS Policy where he spearheaded the development of PEPFAR, and coordinated the successful legislative strategy resulting in the passage by Congress of the U.S. Leadership against HIV/AIDS, Tuberculosis, and Malaria Act of 2003. Previously, Dr. O'Neill also served as the Acting Director of the Office of HIV/AIDS Policy in the Department of Health and Human Services, coordinating the Department's $30 billion HIV/AIDS program.He also served as Director of the HIV/AIDS Bureau of the Health Resources and Services Administration, responsible for management of the $1.9 billion Ryan White CARE program, the nation's largest healthcare program serving people living with AIDS. "I can't think of a more capable and accomplished person than Joe O'Neill to lead our Company into its next era," said Bob Knowling, Chairman of the Board of The Immune Response Corporation."Joe brings a unique perspective from his work on the front lines treating patients and his understanding of the plight of those suffering from this epidemic, combined with unparalleled experience implementing global health initiatives.We are honored that he will put that same passion, dedication and experience to work at the Immune Response Corporation." Dr. O'Neill is a practicing HIV/AIDS physician and a member of the faculties of the Johns Hopkins School of Medicine and the University of Maryland School of Medicine.He was also previously on the medical staff of the Chase Brexton Clinic, a community-based AIDS clinic in Baltimore.A graduate of the School of Medicine of the University of California at San Francisco, Dr. O'Neill also received Master's degrees in public health and medical sciences and a Bachelor's degree in business administration from the University of California at Berkeley. To further align Dr. O'Neill's interests with those of Immune Response stockholders, the Company's Board of Directors granted Dr. O'Neill an inducement stock option award.NASDAQ rules require disclosure of the terms of such awards.Dr. O'Neill received an option to buy 6,000,000 shares of Immune Response common stock at an exercise price of $0.32 per share.The option is subject to vesting requirements, as follows: 3,000,000 of the options shall vest quarterly over two years subject to Dr. O'Neill's continuation of service as CEO; and the remaining 3,000,000 options shall all vest in 2012, subject to Dr. O'Neill's continuation of service as CEO, unless they vest earlier based upon attainment of performance milestones which may be mutually agreed upon in the future by the Company and Dr. O'Neill. Forward-looking Statements This news release contains forward-looking statements.Forward-looking statements are often signaled by forms of words such as should, could, will, might, plan, projection, forecast, expect, guidance, potential and developing.Actual results could vary materially from those expected due to a variety of risk factors, including whether the Company will continue as a going concern and successfully raise proceeds from financing activities sufficient to fund operations and additional clinical trials of REMUNE®, NeuroVax(TM) or IR103, the uncertainty of successful completion of any such clinical trials, the fact that the Company has not succeeded in commercializing any drug, the risk that REMUNE®, NeuroVax(TM) or IR103 might not prove to be effective as either a therapeutic or preventive vaccine, whether future trials will be conducted and whether the results of such trials will coincide with the results of REMUNE®, NeuroVax(TM) or IR103 in preclinical trials and/or earlier clinical trials, and any transition issues related to the hiring of Dr. O'Neill.


Similar Profiles

city

Browse ZoomInfo's Business
Contact Directory by City

city

Browse ZoomInfo's
Business People Directory

city

Browse ZoomInfo's
Advanced Company Directory